Alzheimer’s disease, the primary cause of dementia in the elderly, imposes a tremendous social and economic burden on modern society.
In Japan, the burden of the disease in 2050 is estimated to be a half a trillion US dollars, a figure equivalent to the government’s annual revenues.
Unfortunately, it has proven very difficult to develop drugs capable of ameliorating the disease. After a tremendous burst of progress in the 1990s, the pace of discoveries has slowed. Dr. Saido believes that part of the difficulty is the inadequacy of current mouse models to replicate the real conditions of Alzheimer’s disease and allow an understanding of the underlying mechanisms that lead to neurodegeneration. In fact, much of the research in Alzheimer’s disease over the past decade may be flawed, as it was based on unrealistic models.
The problem with older mouse models is that they overexpress a protein called amyloid precursor protein, or APP, which gives rise to the amyloid-beta (Abeta) peptides that accumulate in the brain, eventually leading to the neurodegeneration that characterizes Alzheimer’s disease. However, in mice the overexpression of APP gives rise to effects which are not seen in human Alzheimer’s disease.
For example, the APP mutant mice often die of unknown causes at a young age, and the group believes this may be related to the generation of toxic fragments of APP, such as CTF-beta. In addition, some of the fragments of APP could be neuroprotective, making it difficult to judge whether drugs are being effective due to their effect on Abeta peptides, which are known to be involved in human AD, or whether it is due to other effects that would not be seen in human disease. In addition, the gene for expressing APP is inserted in different places in the genome, and may knock out other genes, creating artifacts that are not seen in humans.
With this awareness, more than a decade ago Dr. Saido launched a project to develop a new mouse model that would allow more accurate evaluation of therapies for the disease. One of the major hurdles involved a part of the gene, intron 16, which they discovered was necessary for creating more specific models.
The first mice model they developed (NL-F/NL-F) was knocked in with two mutations found in human familial Alzheimer’s disease. The mice showed early accumulation of Abeta peptides, and importantly, were found to undergo cognitive dysfunction similar to the progression of AD seen in human patients. A second model, with the addition of a further mutation that had been discovered in a family in Sweden, showed even faster initiation of memory loss.
These new models could help in two major areas. The first model, which expresses high levels of the Abeta peptides, seems to realistically model the human form of AD, and could be used for elucidating the mechanism of Abeta deposition. The second model, which demonstrates AD pathology very early on, could be used to examine factors downstream of Abeta-40 and Abeta-42 deposition, such as tauopathy, which are believed to be involved in the neurodegeneration. These results may eventually contribute to drug development and to the discovery of new biomarkers for Alzheimer’s disease. The group is currently looking at several proteins, using the new models, which have potential to be biomarkers.
According to Dr. Saido, “We have a social responsibility to make Alzheimer’s disease preventable and curable. The generation of appropriate mouse models will be a major breakthrough for understanding the mechanism of the disease, which will lead to the establishment of presymptomatic diagnosis, prevention and treatment of the disease.”
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimer’s Association Conference in San Diego Links Poverty to Dementiaon August 2, 2022 at 9:24 pm
According to the findings, people who experience personal and neighborhood conditions such as low income, high unemployment, low car/home ownership rates and household overcrowding were significantly ...
- Walk to End Alzheimer’s set for Oct. 1on August 2, 2022 at 8:59 pm
HUNTINGTON — Huntington area residents are invited to join the Alzheimer’s Association Walk to End Alzheimer’s on Saturday, Oct. 1, at the Mountain Health Arena in Huntington. On walk day, ...
- Could Common Viruses be Triggering Alzheimer's?on August 2, 2022 at 5:27 pm
Recent allegations of research misconduct have called years of Alzheimer's research into question. The controversy surrounds papers that identified a toxic oligomer. | Neuroscience ...
- Blood Test Spots Signs of Alzheimer's Years Before Symptoms Appear: Scientistson August 2, 2022 at 11:59 am
Scientists have created a sensor that can detect signs of the condition years before they first manifest themselves.
- Alzheimer's study controversy: What does it mean for future research?on August 2, 2022 at 10:10 am
A seminal study on Alzheimer's disease has come under fire for alleged image manipulation. What does this mean for dementia research, and what are some ways forward?
- As new Alzheimer’s drugs have failed, scientists are shifting focus to other potential causeson August 2, 2022 at 9:05 am
Toxic plaque buildup in the brain may play a role in the disease, but in the search for effective treatments, researchers are looking to other potential causes.
- As new Alzheimer’s drugs keep failing scientists shift focuson August 2, 2022 at 9:05 am
Do new drugs for Alzheimer's work? Getting rid of amyloid plaques has failed to help patients with dementia so scientists are looking for new treatment targets.
- Where are we now in the fight against Alzheimer's?on August 2, 2022 at 8:35 am
Scientists around the world have continued to chip away at the genetic underpinning of this heartbreaking disease that steals the mind, leaving the body empty of its former self.
- What allegations of Alzheimer's research fraud mean for patientson August 2, 2022 at 6:50 am
Alzheimer's disease is the most prevalent form of dementia and, with a rapidly aging global population, it is fueling unprecedented demand for costly patient care. There have been an estimated 400 ...
- AdventHealth Orlando one of 7 sites worldwide to participate in Alzheimer’s studyon August 2, 2022 at 2:00 am
The Alzheimer's study aims to increase early detection. It is still enrolling new participants and is available in Spanish.
via Bing News